Use of human chorionic gonadotropin in the prevention of breast cancer

Women's Health

Volumn 4, Issue 1, 2008, Pages 1-5

  Russo, Irma H ^a   Russo, Jose ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CHORIONIC GONADOTROPIN; ESTROGEN RECEPTOR ALPHA; INHIBIN; PLACEBO; PROTEIN P53; RECOMBINANT CHORIONIC GONADOTROPIN;

AGE DETERMINATION; ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; EDITORIAL; FEMALE; GENE MUTATION; HUMAN; MASTECTOMY; NONHUMAN; PREGNANCY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIATION EXPOSURE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; TREATMENT DURATION; WOMEN'S HEALTH;

BREAST; BREAST NEOPLASMS; CHORIONIC GONADOTROPIN; CLINICAL TRIALS AS TOPIC; FEMALE; GENES, BRCA1; HUMANS; PARITY; PREGNANCY; RISK;

EID: 38049169197     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.1.1     Document Type: Editorial

References (49)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006).
2. Howe HL, Wingo PA, Thun MJ et al.: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl Cancer-Inst. 93, 824-842 (2001).
3. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA: Global trends in breast cancer incidence and mortality 1973-1997. Int. J. Epidemiol. 34(2), 405-412 (2005).
4. Boice JD Jr, Preston D, Davis FG, Monson RR: Frequent chest x-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Rad. Res. 125, 214-222 (1991).
5. Clemons M, Loijens L, Goss P: Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 26(4), 291-302 (2000).
6. Cutuli B, Borel C, Dhermain F et al.: Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother. Oncol. 59(3), 247-255 (2001).
7. Band PR, Le ND, Fang R, Deschamps M: Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360(9339), 1044-1049 (2002).
8. Russo J, Mallo D, Hu Y-F, Balogh G, Sheriff F, Russo IH: Breast differentiation and its implications in cancer prevention. Clin. Cancer Res. 11, S931-S936 (2005).
9. Russo J, Balogh GA, Chen J et al.: The concept of stern cell in the mammary gland and its implication in morphogenesis, cancer and prevention. Front. Biosci. 11, 151-172 (2006).
10. Russo J, Balogh GA, Russo IH; FCCC Hospital Network Participants: Full term pregnancy induces a specific genomic signature in the human breast. Cancer Epidemiol. Biomarkers Prev. (2007) (In Press).
11. McTavish KJ, Jimenez M, Walters KA et al.: Rising follicle-stimulating hormone levels with age accelerate female reproductive failure. Endocrinology 148(9), 4432-4439 (2007).
12. Barrett JR: Fertile grounds of inquiry: environmental effects on human reproduction. Environ. Health Perspect. 114(11), A644-A649 (2006).
13. Sullivan R: An inconceivable truth - the link between infertility and the environment. Vogue August, 246-279 (2007).
14. MacMahon B: Epidemiology and the causes of breast cancer. Int. J. Cancer. 118(10), 2373-2378 (2006).
15. de Waard F, Thijssen JH: Hormonal aspects in the causation of human breast cancer: epidemiological hypotheses reviewed, with special reference to nutritional status and first pregnancy. J. Steroid Biochem. Mol. Biol. 97(5), 451-458 (2005).
16. Russo J, Russo IH: Susceptibility of the mammary gland to carcínogenesis. II. Pregnancy interruption as a risk factor in tumor incidence. Am. J. Pathol. 100, 497-512 (1980).
17. Russo J, Russo IH: Is differentiation the answer in breast cancer prevention? International Research Communications System (IRCS) Med. Sci. 10, 935-941 (1982).
18. Russo J, Rivera R, Russo IH: Influence of age and parity on the development of the human breast. Breast Cancer Res. Treat. 23, 211-218 (1992).
19. Russo J, Russo IH: Biological and Molecular Basis of Breast Cancer. Springer-Verlag, Heidelberg, Germany (2004).
20. Lohstroh PN, Overstreet JW, Stewart DR et al.: Secretion and excretion of human chorionic gonadotropin during early pregnancy. Fertil. Steril. 83(4), 1000-1011 (2005).
21. Lohstroh PN, Overstreet JW. Stewart DR, et al.: Hourly human chorionic gonadotropin secretion profiles during the peri-implantation period of successful pregnancies. Fertil. Steril. 87(6), 1413-1418 (2007).
22. King MC, Wieand S, Hale K et al.: Tamoxifen and breast cancer incidence among women with inherited mutations in BRC41 and BRC42: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286, 2251-2256 (2001).
23. Ganesan S, Richardson AL, Wang ZC et al.: Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 93-97 (2005).
24. Russo IH, Koszalka M, Russo J: Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis. Br. J. Cancer 64, 481-484 (1991).
25. Hertz R: Early studies of chorionic gonadotropin and antihormones. In: Chorionic Conadotropin. Segal SJ (Ed.). Plenum Press, NY, USA and London, UK, 1-15 (1980).
26. Haimov-Kochman R, Sciaky-Tamir Y, Hurwitz A: Reproduction concepts and practices in ancient Egypt mirrored by modern medicine. Eur. J. Obstet. Gynecol. Reprod. Biol. 123(1), 3-8 (2005).
27. Leshem Y, Lunenfeld B: Gonadotropin promotion of adventitious root production on cuttings of Begonia semperflorens and Vitis vinifera. Plant Physiol. 43(3), 313-317 (1968).
28. Finkelstein M: In memoriam. Professor Bernard Zondek. Int. J. Fertil. 12(3), 285-287 (1967).
29. Birken S, Canfield RE: Chemistry and immunochemistry of humal chorionic gonadotropin. In: Chorionic Gonadotropin. Segal SJ (Ed.). Plenum Press. NY, USA and London, UK 65-88, (1980).
30. Leavitt S: A private little revolution - the home pregnancy test in American culture. Bull. History Med. 80(2), 317-345 (2006).
31. Kliesch S, Behre HM, Nieschlag E: High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. Eur. J. Endocrinol. 131, 347-354 (1994).
32. Pfeffer U, Bisacchi D, Morini M et al.: Human chorionic gonadotropin inhibits Kaposi's sarcoma associated angiogenesis, matrix metalloprotease activity, and tumor growth. Endocrinology 43(8), 3114-3121 (2002)
33. Vogt T, Belluscio D: Controversies in plastic surgery: suction-assisted lipectomy (SAL) and the hCG (human chorionic gonadotropin) protocol for obesity treatment. Aesthetic Plast. Surg. 11(3), 131-156 (1987).
34. Wilken JA, Bedows E: A novel four-amino acid determinant defines conformational freedom within chorionic gonadotropin β-subunits. Biochem. 46, 4417-4424 (2007).
35. Chang F, Kenley S, Burns T et al.: Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. Fertil. Steril. 76, 67-74 (2001).
36. The European Recombinant Human Chorionic Gonadotrophin Study Group: Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment - recombinant HCG versus urinary HCG. Hum. Reprod. 15, 1446-1451 (2000).
37. Russo IH, Slater C, Lareef MH et al.: Recombinant human chorionic gonadotropin (r-hCG) reduces the incidence and progression of mammary tumors in the rat. Breast Cancer Res. Teatment 64, 50, 160a (2000).
38. Janssens JP, Russo J, Russo I et al.: Human chorionic gonadotropin (hCG) and prevention of breast cancer. Mol. Cell Endocrinol. 269(1-2), 93-98 (2007).
39. Wooster R, Neuhausen SL, Mangion J et al.: Localization of a breast cancer susceptibility gene, BRC42, to chromosome 13q12-13. Science 265(5181), 2088-2090 (1994).
40. Bernstein JL, Langholz B, Haile RW et al.: Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. Breast Cancer Res. 6(3), R199-R214 (2004).
41. Manuguerra M, Matullo G, Veglia F et al.: Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis 28(2), 414-422 (2007).
42. Lakhani SR, Jacquemier J, Sloane JP et al.: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRC42 mutations, J. had Cancer Inst. 90(15), 1138-1145 (1998).
43. Palli D, Masala G, Mariani-Costantini R et al.: A gene-environment interaction between occupation and BRCA1/BRC42 mutations in male breast cancer? Eur. J Cancer 40(16), 2474-2479 (2004).
44. Laakso M, Tanner M, Nilsson J et al.: Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin. Cancer Res. 12(14 Pt 1), 4185-4191 (2006).
45. Ganesan S, Richardson AL, Wang ZC et al.: Dana-Farber Cancer abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 93-97 (2005).
46. McGregor, Land CE, Choi K et al.: Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagaski 1950-1989. J. Natl Cancer Inst. 59, 799-811 (1977).
47. Cutuli B, Borel C, Dhermain F et al.: Breast cancer occurred after treatment for Hodgkids disease: analysis of 133 cases. Radiother. Oncol. 59(3), 247-255 (2001).
48. Clarke CA, Purdie DM, Glaser SL: Population attributable risk of breast cancer in white women associated with Immediately modifiable risk factors. BMC Cancer 6, 170 (2006).
49. Key J, Hodgson S, Omar RZ et al.: Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control 17, 759-770 (2006).